Affiliation:
1. Laboratory of Cellular and Molecular Pharmacology, Section of Neurosciences, Department of Biomedical Sciences, University of Cagliari, Monserrato, 09042 Cagliari, Italy
Abstract
Lysophosphatidic acid (LPA) is a well-documented pro-oncogenic factor in different cancers, but relatively little is known on its biological activity in neuroblastoma. The LPA effects and the participation of the tyrosine kinase receptor anaplastic lymphoma kinase (ALK) in LPA mitogenic signaling were studied in human neuroblastoma cell lines. We used light microscopy and [3H]-thymidine incorporation to determine cell proliferation, Western blot to study intracellular signaling, and pharmacological and molecular tools to examine the role of ALK. We found that LPA stimulated the growth of human neuroblastoma cells, as indicated by the enhanced cell number, clonogenic activity, and DNA synthesis. These effects were curtailed by the selective ALK inhibitors NPV-TAE684 and alectinib. In a panel of human neuroblastoma cell lines harboring different ALK genomic status, the ALK inhibitors suppressed LPA-induced phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2), which are major regulators of cell proliferation. ALK depletion by siRNA treatment attenuated LPA-induced ERK1/2 activation. LPA enhanced ALK phosphorylation and potentiated ALK activation by the ALK ligand FAM150B. LPA enhanced the inhibitory phosphorylation of the tumor suppressor FoxO3a, and this response was impaired by the ALK inhibitors. These results indicate that LPA stimulates mitogenesis of human neuroblastoma cells through a crosstalk with ALK.
Reference65 articles.
1. LPA receptor signaling: Pharmacology, physiology, and pathophysiology;Yung;J. Lipid Res.,2014
2. Role of lysophosphatidic acid and its receptors in health and disease: Novel therapeutic strategies;Geraldo;Signal Transduct. Target Ther.,2021
3. Xu, Y. (2019). Targeting lysophosphatidic acid in cancer: The issues in moving from bench to bedside. Cancers, 11.
4. Balijepalli, P., Sitton, C.C., and Meier, K.E. (2021). Lysophosphatidic acid signaling in cancer cells: What makes LPA so special?. Cells, 10.
5. LPA receptor subtypes and biological actions;Choi;Annu. Rev. Pharmacol. Toxicol.,2010